News Archives - Page 1552 of 1552

WednesdaySep 21, 2016 2:02 pm

Peregrine Pharmaceuticals, Inc. (PPHM, PPHMP) Issues Update on Presentation of Top-Line Data at European Society for Medical Oncology

Peregrine Pharmaceuticals (NASDAQ: PPHM, PPHMP) reports that it will present top-line data from the phase 3 SUNRISE trial of its bavituximab cancer treatment as a late-breaking oral presentation at the upcoming European Society for Medical Oncology (ESMO) 2016 Congress. The company will present data showing that a biomarker in the SUNRISE trial correlated with a statistically significant improvement in overall survival for patients treated with bavituximab in combination with docetaxel compared to patients treated with docetaxel alone. Peregrine will file a new patent application directed to the use of the biomarker prior to the presentation of results at the ESMO…

WednesdaySep 21, 2016 1:50 pm

Eleven Biotherapeutics, Inc.’s (EBIO) Acquisition of Viventia Bio Creates Targeted Protein Therapeutics Oncology Company

Through a share purchase agreement, Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) has acquired Viventia Bio, Inc., creating a single entity focused on the development of novel treatments in areas of oncology with significant unmet need. In addition to other drug candidates, Eleven’s pipeline now includes Viventias’ two lead product candidates: Vicinium, in a phase 3 clinical trial for high-grade non-muscle invasive bladder cancer (NMIBC), with topline data expected in the first half of 2018; and Proxinium, expected to enter phase 2 development in early 2017 for the treatment of late-stage squamous cell carcinoma of the head and neck. To view the…

WednesdaySep 21, 2016 7:43 am

BioLineRx Ltd. (BLRX) Initiates Phase 2a Trial for Pancreatic Cancer Therapy

BioLineRx Ltd. (NASDAQ: BLRX) announced that it has initiated a Phase 2a trial investigating BL-8040 in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy, in patients with metastatic pancreatic cancer. The study is designed to evaluate the safety and efficacy of the combination of BL-8040 and KEYTRUDA in up to 30 subjects with metastatic pancreatic adenocarcinoma. The study is designed to evaluate the clinical response, safety and tolerability of the combination of these therapies as well as multiple pharmacodynamic parameters, including the ability to improve infiltration of T cells into the tumor and their reactivity. To view the full press release,…

WednesdaySep 21, 2016 7:40 am

Airgain, Inc. (AIRG) Announces Q2 2016 Financial Results

Airgain, Inc. (NASDAQ : AIRG) today reported results for the second quarter ended June 30, 2016. Sales increased 63% to $9.9 million year over year, gross profit increased 79% to $4.5 million year over year, total operating expenses increased 31% year over year, and net income attributable to common stockholders totaled $700,428 versus a loss of $781,689 a year ago. Other key metrics include a 62% increase in total customer devises to 12 million, a 24% increase in the average number of antennas per device, and a 1% decrease in the average selling price per device. To view the full…